Evidence map›Paper›PMID 35950735›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023

An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.

Sebastian Palmqvist, Erik Stomrud, Nicholas Cullen, Shorena Janelidze, Ekaterina Manuilova, Alexander Jethwa, Tobias Bittner, Udo Eichenlaub, Ivonne Suridjan, Gwendlyn Kollmorgen and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 6 pooled it
22.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 6 syntheses or guidelines pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Meta-Analysis of Transcriptomic Studies of Blood and Six Brain Regions Identifies a Consensus of 15 Cross-Tissue Mechanisms in Alzheimer's Disease and Suggests an Origin of Cross-Study Heterogeneity.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2025
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Reduced Effect ofNeurology. Genetics · 2026
    Article
  14. Article
  15. Review
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 4 countries.

Sebastian PalmqvistClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Erik StomrudClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Nicholas CullenClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Shorena JanelidzeClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Ekaterina ManuilovaRoche Diagnostics GmbH, Penzberg, Germany.
Alexander JethwaRoche Diagnostics GmbH, Penzberg, Germany.
Tobias BittnerF. Hoffmann-La Roche AG, Basel, Switzerland.
Udo EichenlaubRoche Diagnostics GmbH, Penzberg, Germany.
Ivonne SuridjanRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Gwendlyn KollmorgenRoche Diagnostics GmbH, Penzberg, Germany.
Matthias RiepeDivision of Geriatric Psychiatry, Ulm University, Ulm, Germany.
Christine A F von ArnimDivision of Geriatrics, University Medical Center Göttingen, Georg-August-University, Goettingen, Germany.
Hayrettin TumaniDepartment of Neurology, University Hospital of Ulm, Ulm, Germany.
Klaus HagerInstitute for General Medicine and Palliative Medicine, Hannover Medical School, Hannover, Germany.
Fedor HeidenreichDepartment of Neurology and Clinical Neurophysiology, Diakovere Krankenhaus Henriettenstift, Hannover, Germany.
Niklas Mattsson-CarlgrenClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Lund University · SERoche Pharma AG (Germany) · DERoche (Switzerland) · CHSkåne University Hospital · SEMedizinische Hochschule Hannover · DENational Hospital for Neurology and Neurosurgery · GBSahlgrenska University Hospital · SEUniversität Ulm · DEUniversity Hospital Ulm · DEUniversity of Göttingen · DEVinzenzkrankenhaus Hannover · DE

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI ARTHUR W TOGA · 2016 to 2026
$226.7M
The effects of iron on oxidative stress and Alzheimer's biomarkers in amyloid-positive and negative elderly normalR01AG068398 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIANG, GLORIA CHIA-YI · 2020 to 2024
$2.8M
NIA NIH HHS R01 AG068398NIA NIH HHS U19 AG024904
6 · The paper itself

Abstract

introductionThere is a great need for fully automated plasma assays that can measure amyloid beta (Aβ) pathology and predict future Alzheimer's disease (AD) dementia.

methodsTwo cohorts (n = 920) were examined: Panel A+ (n = 32 cognitively unimpaired [CU], n = 106 mild cognitive impairment [MCI], and n = 89 AD) and BioFINDER-1 (n = 461 CU, n = 232 MCI). Plasma Aβ42/Aβ40, phosphorylated tau (p-tau)181, two p-tau217 variants, ApoE4 protein, neurofilament light, and GFAP were measured using Elecsys prototype immunoassays.

resultsThe best biomarker for discriminating Aβ-positive versus Aβ-negative participants was Aβ42/Aβ40 (are under the curve [AUC] 0.83-0.87). Combining Aβ42/Aβ40, p-tau181, and ApoE4 improved the AUCs significantly (0.90 to 0.93; P< 0.01). Adding additional biomarkers had marginal effects (ΔAUC ≤0.01). In BioFINDER, p-tau181, p-tau217, and ApoE4 predicted AD dementia within 6 years in CU (AUC 0.88) and p-tau181, p-tau217, and Aβ42/Aβ40 in MCI (AUC 0.87). DISCUSSION: The high accuracies for Aβ pathology and future AD dementia using fully automated instruments are promising for implementing plasma biomarkers in clinical trials and clinical routine.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesApolipoprotein E4BiomarkersHumanstau ProteinsAmyloid beta-PeptidesApolipoprotein E4Biomarkerstau ProteinsAlzheimer's diseaseamyloid betaapolipoprotein Earea under the curvebloodcerebrospinal fluidclinical practicecognitively unimpaireddiagnosticsElecsysfully automated instrumentsglial fibrillary acidic proteinimmunoassaysimplementationmild cognitive impairmentneurofilament lightphosphorylated tauplasmapredictionprognostics

Identifiers

PMID35950735
PMCPMC9918613
OpenAlexW4292791024

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.